title: [Treatment of malignant lymphoma by autologous hematopoietic stem cell transplantation combined with high dose radiotherapy and chemotherapy].
abstract: OBJECTIVE
  To investigate the effects of treatment of malignant lymphoma (ML) by autologous hematopoietic stem cell transplantation (AHSCT) combined with high dose radiotherapy and chemotherapy.
  
  
  METHODS
  From June 1991 to October 2002, 56 patients, aged 9 - 65 years, with ML, 44 non-Hodgkin's lymphoma (NHL) and 12 Hodgkin's disease (HD) were treated with AGSCT combined with high dose radiotherapy and chemotherapy. Among them, 12 received autologous bone marrow transplantation (ABMT) and 44 received autologous peripheral blood stem cell transplantation (APBSCT), In the latter the APBSCs were mobilized by carboplatin and etoposide (CE) or CHOP (CTX, ADM, VCR, PDN) plus granulocyte-colony stimulating factor (G-CSF) and/or granulocyte-macrophage colony stimulating factor (GM-CSF) 10 micro g/kg/d. Pretreatment included BEAM (BCNU, Vp-16, AraC, MEL) or MEL 140 mg/m(2) + Vp-16,200 mg/L total body irradiation (TBI) 8 Gy. The patients were flowed up for 40 - 4,310 days with a median of 1,820 days.
  
  
  RESULTS
  Hematopoietic reconstruction was observed in all patients. The 1, 2, and 5-year disease-free survival rates were 87.5%, 60.7%, and 57.1% respectively, with the longest survival of 11 years. Fourteen patients developed relapse. No transplantation-related death was seen.
  
  
  CONCLUSIONS
  Autologous hematopoietic stem cell transplantation combined with high dose radiotherapy and chemotherapy is effective on Ml. AHSCT shows a more rapid effect on hematopoietic reconstruction than ABMT.
authors.affiliation: Department of Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin 300060, China.
authors.forename: Hua-qing
authors.initials: HQ
authors.lastname: Wang
authors.forename: Xiu-zhen
authors.initials: XZ
authors.lastname: Cui
authors.forename: Xiu-bao
authors.initials: XB
authors.lastname: Ren
authors.forename: Xian-ming
authors.initials: XM
authors.lastname: Liu
authors.forename: Rong-zeng
authors.initials: RZ
authors.lastname: Dai
authors.forename: Hui-lai
authors.initials: HL
authors.lastname: Zhang
authors.forename: Wen-yang
authors.initials: WY
authors.lastname: Huang
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Xi-shan
authors.initials: XS
authors.lastname: Hao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014182:Transplantation, Autologous